FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk
On Nov. 9, 2026, the U.S. Food and Drug Administration (FDA) approved Bayer’s Sunharbo (asundexian) 50 mg tablets,…
-
-
Agriculture | Biotechnology | Life Science History | Medical Device | Nanotechnology | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | Veterinary
LifeScienceHistory.com Releases Life Science Genealogy Poster for University of California, Berkeley
On Nov. 8, 2026, a Life Science Genealogy poster spotlighting University of California, Berkeley spin-off companies was published…
-
Agriculture | Biotechnology | Life Science History | Medical Device | Nanotechnology | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | Veterinary
Genealogy Poster Illustrates Spin-Off Companies from Washington’s Universities and Non-Profit Research Organizations
On Nov. 7, 2026, a Life Science Genealogy poster that illustrates spin-off companies from Washington’s Universities and Non-Profit…
-
Agriculture | Biotechnology | Life Science History | Medical Device | Nanotechnology | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | Veterinary
LifeScienceHistory.com Releases Life Science Genealogy Poster for University of Washington
On Nov. 6, 2026, a Life Science Genealogy poster spotlighting University of Washington spin-off companies was published by…
-
Artificial Intelligence | Biotechnology | Infectious Disease | Medical Device | Nanotechnology | Neurology | NIH | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics
Bioengineered retracts 119 more papers as investigation into Paper Mills continues
On Nov. 3, 2026, Bioengineered retracted 119 papers in October amid investigations into suspected paper mill activity and…
-
Cambrex Breaks Ground on $120 Million Expansion in Charles City, Iowa
On Oct. 30, 2026, Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the groundbreaking of…
-
Biotechnology | Chemistry | FDA | Oncology | Pharmaceutical
Merck Drug Reduces Risk of Death by 32% Compared to Chemotherapy Awarded FDA Priority Review
On Oct. 26, 2026, Merck announced the first results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab…
-
Artificial Intelligence | Biotechnology | Clinical Research | Diagnostics | Genomics | Medical Device | Pharmaceutical | Therapeutics
OpenAI acquires Orchestra Bio Platform
On Oct. 20, 2026, OpenAI announced it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate…
-
Merck to Acquire Silence Therapeutics for $1.3 Billion, Strengthening Rare Disease Platform
On Oct. 19, 2026, Merck announced it it has entered into a definitive agreement to acquire Silence Therapeutics,…
-
China’s Hansoh Pharma strikes drug deal with Roche worth over $15 billion
On Oct. 19, 2026, China’s Hansoh Pharmaceutical reported it has entered into a partnership and licensing deal with…
-
GSK to Invest Over $800 Million to Expand Operations in Pennsylvania, Creating Over 300 New Jobs
On Oct. 9, 2026, the Pennsylvania Governor’s Office announced the Commonwealth has secured an over $800 million investment…
-
Viatris Agrees to Acquire Pacira BioSciences for $1.65 billion in Cash, Becoming a Leader in Non-Opioid Pain Therapies
On Oct. 8, 2026, Viatris, a global healthcare company, and Pacira BioSciences, a leader in innovative non-opioid pain…
-
Utah approves slew of health AI pilots for drug management, women’s health
On Oct. 6, 2026, the state of Utah expanded its controversial healthcare AI program with three new pilots…
-
Biotechnology | CMO | CRO | Pharmaceutical
Thewaico Emerges from Stealth with Bioreactor Platform Built to Address Biomanufacturing’s Massive Scale-Up Problem
On Sept. 30, 2026, Thewaico, a bioprocess innovation company, today emerged from stealth with an integrated bioreactor and…
-
AN2 Therapeutics Announces Extension of Gates Foundation Funding for Tuberculosis Research with GSK
On Sept. 28, 2026, AN2 Therapeutics, a clinical stage pharmaceutical company focused on the discovery and development of…
-
US FDA approves AbbVie’s drug for Parkinson’s disease
On Sept. 25, 2026, the US Food and Drug Administration announced approval of AbbVie’s treatment for Parkinson’s disease…
-
Biotechnology | CDC | Chemistry | Clinical Research | Cosmetic | FDA | Infectious Disease | NIH | Non-Profit Research | Oncology | Pharmaceutical | Therapeutics | U.S. Congress | Veterinary
HHS Accelerates Shift to Human-Based Research, Reduces Reliance on Animal Testing
On Sept. 21, 2026, the U.S. Department of Health and Human Services (HHS) announced a new wave of…
-
Biotechnology | FDA | Medical Device | Oncology | Organoids | Pharmaceutical | Rare Disease | Robotics | Stem Cell | Telemedicine | Therapeutics | Vaccine | Women's Health
FDA Launches Expedited IND Pilot Program, Begins Accepting Applications
On Sept. 15, 2026, the U.S. Food and Drug Administration announced the final design of the Expedited Investigational…
-
Google DeepMind Launches AlphaGenome Atlas: A predictive map of every possible DNA letter change in the human genome
On Sept. 8, 2026, Google DeepMind released the AlphaGenome Atlas: a platform containing predictions for the effects of…
-
ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients
On Sept. 3, 2026, Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved ZANVASTRO™…
-
Vertex Completes Acquisition of Crinetics Pharmaceuticals for $10 Billion
On Sept. 1, 2026, Vertex Pharmaceuticals announced the successful completion of the acquisition of Crinetics Pharmaceuticals, a global…
-
White House Announces Deal with Nine Mid-Size Pharmacutical Companies to Lower Drug Prices
On Aug. 31, 2026, the White House announced agreements with nine- mid-sized pharmaceutical manufacturers to lower prescription drug…
-
Artificial Intelligence | Biotechnology | CRISPR | Genomics | Oncology | Pharmaceutical | Therapeutics
Scientists Decode Gene Circuits of Human Immunity, Fueling New Era of Disease Research
On Aug. 28, 2026, scientists from Gladstone Institutes, UC San Francisco, and Stanford University, in collaboration with Biohub,…
-
Haisco Signs $1.5 Billion Licensing Deal With Sentivera, A New U.S. Venture
On Aug. 25, 2026, Haisco Pharmaceutical Group announced on that it has entered into an exclusive licensing agreement…
-
BioMarin to Acquire Alesta Therapeutics in Deal Valued at $490 Million to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia
On Aug. 18, 2026, BioMarin Pharmaceutical announced a definitive agreement to acquire Alesta Therapeutics to gain Alesta’s lead…
-
Bristol Myers Squibb Announce New $2.3 Billion Manufacturing Campus in Houston
On Aug. 10, 2026, Bristol Myers Squibb (BMS) announced the selection of Houston, Texas, as the site for…
-
Biotechnology | Diagnostics | Infectious Disease | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics | Vaccine | Women's Health
Gates Foundation provides $540 Million landmark grant to the Institute for Health Metrics and Evaluation
On Aug. 10, 2026, the Institute for Health Metrics and Evaluation (IHME), an independent research organization at the…
-
FDA Approves Tylenol Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief
On Jul. 24, 2026, U.S. Food and Drug Administration (FDA) approved Tylenol with Naproxen (acetaminophen 325 mg/naproxen sodium…
-
Biotechnology | Disease | HIV | Pharmaceutical | Therapeutics | WHO
Merck licenses experimental HIV pill to generic makers in 129 countries
On Jul. 24, 2026, Merck announced it has signed seven voluntary licensing agreements with generic drug manufacturers to…
-
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for Treatment of ADHD
On Jul. 24, 2026, Otsuka Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted approval…
